Price
$215.33+6.98%Social Signal Score
Analyst Ratings
42 analystsRevenue
$23.18B+278.66%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Susan Patricia Griffith
- Sector
- Financial Services
- Industry
- Insurance - Property & Casualty
- Employees
- 70,053
- Beta
- 0.23
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 2.70
Financials
Revenue
$23.18B+278.7%Net Income
$2.54B+563.4%EBITDA
$3.32B+425.0%Free Cash Flow
$4.40B+1030.5%EPS (diluted)
$4.37+562.1%Shares Outstanding (diluted)
582.20M+0.3%Operating Expenses
$0.00Cash & Debt
$99.34BReturn of Capital
$529.00MRevenue by Segment (annual)
$82.86BDividend per Share
$0.10Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $87.64B | $11.31B | $19.29 |
| 2024 | $75.34B | $8.48B | $14.45 |
| 2023 | $62.08B | $3.90B | $6.61 |
| 2022 | $49.59B | $722.00M | $1.19 |
| 2021 | $47.68B | $3.35B | $5.69 |
| 2020 | $42.64B | $5.70B | $9.71 |
| 2019 | $39.00B | $3.97B | $6.75 |
| 2018 | $31.95B | $2.62B | $4.49 |
| 2017 | $26.82B | $1.59B | $2.74 |
| 2016 | $23.42B | $1.03B | $1.77 |
| 2015 | $20.83B | $1.27B | $2.16 |
| 2014 | $19.38B | $1.28B | $2.17 |
| 2013 | $18.16B | $1.17B | $1.95 |
| 2012 | $17.07B | $902.30M | $1.50 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from PGR's reported EPS growth of 21.7% a year over 13 years.
- EPS in 5 years
- $51.49
- Implied price
- $617.87
- Return from $229.96
- 21.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $307.19 — today's price is already 25.1% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 8 | 10 | 12 | 14 | 16 |
|---|---|---|---|---|---|
| 11.7% | 3.1% | 7.8% | 11.8% | 15.3% | 18.5% |
| 16.7% | 7.7% | 12.7% | 16.9% | 20.5% | 23.8% |
| 21.7% | 12.4% | 17.5% | 21.9% | 25.7% | 29.1% |
| 26.7% | 17.0% | 22.3% | 26.9% | 30.8% | 34.4% |
| 31.7% | 21.6% | 27.1% | 31.9% | 36.0% | 39.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-57.78%Social Signal Score
Mentions (48)
- Newszacks.com·3d ago·Neutral
Progressive's October Earnings Decline Y/Y on Escalating Expenses PGR's October 2026 earnings slip 1% as rising expenses pressure results, despite higher revenues and vehicle policy growth.
View source ↗ - Newszacks.com·4d ago·Positive
Why Progressive (PGR) is a Top Momentum Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·4d ago·Neutral
The Progressive Corporation (PGR) Is a Trending Stock: Facts to Know Before Betting on It Recently, Zacks.com users have been paying close attention to Progressive (PGR). This makes it worthwhile to examine what the stock has in store.
View source ↗ - Newsglobenewswire.com·4d ago·Neutral
Progressive Reports October 2026 Results MAYFIELD VILLAGE, OHIO, Nov. 18, 2026 (GLOBE NEWSWIRE) -- The Progressive Corporation (NYSE:PGR) today reported the following results for the month ended October 31, 2026:
View source ↗ - News247wallst.com·6d ago·Neutral
Progressive Has Paid $13.90 Per Share in Dividends This Year, and $1,000 From a Decade Ago Is Now Worth More Than $8,000 Switching car insurers might save you a few dollars a month, but one investor move would have paid far more. Progressive's pricing edge, a lumpy annual payout, and a lukewarm Wall Street all shape what comes next.
View source ↗ - Newszacks.com·9d ago·Neutral
Why Is Progressive (PGR) Up 10.2% Since Last Earnings Report? Progressive (PGR) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·17d ago·Neutral
Investors Heavily Search The Progressive Corporation (PGR): Here is What You Need to Know Zacks.com users have recently been watching Progressive (PGR) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
View source ↗ - Newsmarketbeat.com·18d ago·Neutral
Progressive Q3 Earnings Call Highlights Progressive NYSE: PGR reported continued premium and policy growth in the third quarter of 2026 while emphasizing underwriting discipline, technology investment and expansion opportunities in bundled auto and home insurance, commercial lines and small business coverage.
View source ↗ - News (RSS)seekingalpha·18d ago·Positive
The Progressive Corporation (PGR) Q3 2026 Earnings Call Transcript
View source ↗ - Newsseekingalpha.com·19d ago·Positive
The Progressive Corporation (PGR) Q3 2026 Earnings Call Transcript The Progressive Corporation (PGR) Q3 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
Progressive Announces Investor Relations Call MAYFIELD VILLAGE, OHIO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- As previously announced, The Progressive Corporation (NYSE: PGR) will host an Investor Relations conference call on Tuesday, November 3, 2026, beginning at 9:30 a.m. eastern time. This quarterly call, which will consist of both a conference call and audio-only webcast, is scheduled to last 60 minutes and will consist of a question-and-answer session with Tricia Griffith, our CEO, and Andrew Qu…
View source ↗ - Newsglobenewswire.com·30d ago·Neutral
Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026 Single-dose miv-cel continues to demonstrate promising clinical benefit in progressive multiple sclerosis, achieving robust CAR T-cell penetration in the central nervous system (CNS) and improving disability scores while removing the need for chronic immunotherapies
View source ↗ - Newsbusinesswire.com·30d ago·Neutral
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026 PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CARTCellTherapy--Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients.
View source ↗ - Newszacks.com·31d ago·Positive
Progressive (PGR) Upgraded to Buy: Here's Why Progressive (PGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newszacks.com·32d ago·Neutral
Progressive's Rising Auto Premiums Support Growth and Underwriting PGR's rising auto premiums, expanding policy base and improved underwriting profitability support growth as competition intensifies in the U.S. auto market.
View source ↗ - Newszacks.com·32d ago·Neutral
Here is What to Know Beyond Why The Progressive Corporation (PGR) is a Trending Stock Progressive (PGR) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
View source ↗ - Newsseekingalpha.com·38d ago·Neutral
Progressive: A Great Insurer, But Slowing Growth Justifies A 'Hold' The Progressive Corp. is rated a 'Hold,' reflecting strong underwriting and durable demand but tempered by slowing premium growth and uncertain earnings momentum. PGR's Q3 2026 combined ratio improved to 88.7%, yet net premiums written grew just 4% YoY, with September monthly growth slowing to 2%. Valuation appears fair at a trailing P/E of 10.7x, but a weaker forward EPS outlook could pressure the multiple and limit upside.
View source ↗ - Newsfool.com·38d ago·Positive
Progressive Stock Has Turned $10,000 Into More Than $90,000 in 10 Years Progressive is the leading auto insurer in the U.S., jumping into first place this year. It has beat its target goal of a 96% combined ratio for the part decade.
View source ↗ - Newsseekingalpha.com·38d ago·Neutral
The Progressive Q3 Panic Is Overdone The Progressive's Q3 was a disappointment, but it isn't a sell signal for me. I'm still holding my shares, and I am maintaining my buy rating. Premium growth came in at 1%, auto policies dropped 31,000 in a month, and the underlying loss ratio hit 68.7, the highest in two years. The combined ratio sits at 88.7, or 91.1 without reserve releases, well under the sub-96 target. Every segment is under 96.
View source ↗ - Newszacks.com·39d ago·Positive
Progressive's Q3 Earnings Top Estimates on Higher Premiums Progressive's Q3 earnings beat estimates as higher premiums and an improved combined ratio boosted results, while September policy growth remained strong.
View source ↗ - Newszacks.com·39d ago·Positive
Progressive (PGR) Q3 Earnings Top Estimates Progressive (PGR) came out with quarterly earnings of $4.6 per share, beating the Zacks Consensus Estimate of $4.46 per share. This compares to earnings of $4.05 per share a year ago.
View source ↗ - Newsglobenewswire.com·39d ago·Neutral
Progressive Reports September 2026 Results MAYFIELD VILLAGE, OHIO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- The Progressive Corporation (NYSE:PGR) today reported the following results for the month and quarter ended September 30, 2026:
View source ↗ - Newszacks.com·41d ago·Neutral
Progressive Set to Report Q3 Earnings: Here's What to Expect Progressive's Q3 earnings are expected to rise 9.4%, aided by premium growth and higher investment income, but rising underwriting costs could weigh on results.
View source ↗ - Newszacks.com·45d ago·Negative
Why the Market Dipped But Progressive (PGR) Gained Today In the closing of the recent trading day, Progressive (PGR) stood at $218.98, denoting a +2.27% move from the preceding trading day.
View source ↗ - Newsglobenewswire.com·46d ago·Neutral
Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026 Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS and no cases of IEC-HS Updated Phase 1 investigator-initiated trial data to be presented, continuing to highlight encouraging clinical activity and a well-tolerated sa
View source ↗ - Newsglobenewswire.com·46d ago·Neutral
Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026 WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, today announced that
View source ↗ - Newszacks.com·52d ago·Neutral
Progressive (PGR) Laps the Stock Market: Here's Why Progressive (PGR) closed the most recent trading day at $210.96, moving +1.76% from the previous trading session.
View source ↗ - Newszacks.com·52d ago·Neutral
Will Progressive (PGR) Beat Estimates Again in Its Next Earnings Report? Progressive (PGR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
View source ↗ - Newszacks.com·52d ago·Positive
Is Trending Stock The Progressive Corporation (PGR) a Buy Now? Progressive (PGR) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - Newszacks.com·55d ago·Neutral
Progressive (PGR) Increases Despite Market Slip: Here's What You Need to Know Progressive (PGR) closed the most recent trading day at $209.47, moving +1.93% from the previous trading session.
View source ↗ - News (RSS)zerohedge·61d ago·Neutral
…ively traded baskets in recent sessions .. There was some chatter yesterday on personal insurance (ALL), with focus today broadening out to Personal Insurance peers (PGR, TRV etc), Lead generators (investors have pointed to a couple of small cap insurance lead generators down HSD % - LDD %), Insurance Brokers (GSHD u/p peers 2 days in a row), Wealth Managers & Retail brokers (SCHW LPPA AMP RJF).. Banks are also trading heavy, and feedback here is debated – but focus does remain on banks with bus…
View source ↗ - News247wallst.com·62d ago·Positive
Progressive's Trailing Yield Is Wildly Misleading. Here Is What It Actually Pays Most income investors screening Progressive see a yield figure and assume it reflects what they will actually collect. The reality is far stranger, and far more consequential for anyone buying shares today.
View source ↗ - Newsfool.com·65d ago·Neutral
What History Says About Insurance Stocks When Bond Yields Rise Rising bond yields can both help and hurt insurance stocks, so the latest Fed rate hike is an important development.
View source ↗ - Newsglobenewswire.com·65d ago·Neutral
Progressive Reports August 2026 Results MAYFIELD VILLAGE, OHIO, Sept. 18, 2026 (GLOBE NEWSWIRE) -- The Progressive Corporation (NYSE:PGR) today reported the following results for the month ended August 31, 2026:
View source ↗ - Newsfool.com·66d ago·Positive
Is Progressive Stock a Buy, Sell, or Hold About 10% Below Its 52-Week High? Progressive is one of the largest property and casualty insurance companies, generally producing strong underwriting results. The stock is down about 10% from its 52-week high and nearly 25% from its 2025 high, but it isn't exactly cheap.
View source ↗ - Newszacks.com·66d ago·Neutral
Is Most-Watched Stock The Progressive Corporation (PGR) Worth Betting on Now? Progressive (PGR) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
View source ↗ - Newsglobenewswire.com·67d ago·Neutral
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer's Disease The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer's Disease, a Progressive Disease The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer's Disease, a Progressive Disease
View source ↗ - Newszacks.com·69d ago·Positive
Progressive (PGR) Gains As Market Dips: What You Should Know In the latest trading session, Progressive (PGR) closed at $221.02, marking a +1.56% move from the previous day.
View source ↗ - Newszacks.com·74d ago·Positive
Can PGR's Telematics Edge Strengthen Its Underwriting Advantage? Progressive's telematics and driving data support risk selection and claims efficiency, while stronger competition raises the need for underwriting discipline.
View source ↗ - Newszacks.com·80d ago·Neutral
Progressive (PGR) Outperforms Broader Market: What You Need to Know In the closing of the recent trading day, Progressive (PGR) stood at $223.91, denoting a +1.14% move from the preceding trading day.
View source ↗ - Newsglobenewswire.com·80d ago·Neutral
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in China The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer's Disease, a Progressive Neurodegenerative Disease The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer's Disease, a Progressive Neurodegenerative Disease
View source ↗ - Newszacks.com·87d ago·Neutral
Progressive (PGR) Stock Drops Despite Market Gains: Important Facts to Note In the closing of the recent trading day, Progressive (PGR) stood at $217.65, denoting a -2.18% move from the preceding trading day.
View source ↗ - News (Marketaux)seekingalpha.com·87d ago·Positive
Progressive: Strong Underwriting, But Limited Margin Of Safety (NYSE:PGR) Progressive: Strong Underwriting, But Limited Margin Of Safety (NYSE:PGR)
View source ↗ - Newszacks.com·94d ago·Negative
Progressive's July Earnings Decline Y/Y on Escalating Expenses PGR's July premiums and policies in force grew, while higher expenses and securities losses pressure earnings and margins.
View source ↗ - Newsglobenewswire.com·95d ago·Neutral
Progressive Reports July 2026 Results MAYFIELD VILLAGE, OHIO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- The Progressive Corporation (NYSE:PGR) today reported the following results for the month ended July 31, 2026:
View source ↗ - Newszacks.com·100d ago·Positive
Berkshire Hathaway vs. Progressive: Which Insurance Powerhouse Leads? PGR edges BRK.B on price gains, analyst sentiment and ROE, as both insurers lean on disciplined underwriting and strong fundamentals.
View source ↗ - Newszacks.com·100d ago·Neutral
Progressive (PGR) Up 1.5% Since Last Earnings Report: Can It Continue? Progressive (PGR) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsfool.com·106d ago·Neutral
Progressive's Combined Ratio Widened to 87.1 Last Quarter. What That Says About the Growth Machine. Progressive has had a good run, but further growth appears to require some trade-offs.
View source ↗
Earnings
Wed, Jan 27(in 2 months)
Consensus estimate $3.98 per share
Typical surprise +0.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Oct 14$4.37 vs $4.35beat
- Wed, Jul 15$4.85 vs $4.64beat
- Wed, Apr 15$4.81 vs $4.85miss
- Wed, Jan 28$4.67 vs $4.44beat
- Wed, Oct 15$4.05 vs $4.99miss
- Wed, Jul 16$4.88 vs $4.43beat
Estimates and results for PGR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PGR officers and directors.
- Bought
- —
- Sold
- $26.4m
0 trades
14 trades
- Broz Stevensold
- Broz Stevensold
- Griffith Susan Patriciasold
- Broz Stevensold
- Niederst Lori Asold
- Quigg Andrew Jsold
- Murphy John Josold
- Griffith Susan Patriciasold
86 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Sep 7, 2026 (52d later)Sell$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Sell$15,001 - $50,000
- Gilbert Cisneroshouse · CA31 · disclosed Jul 3, 2026 (17d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed May 13, 2026 (30d later)Buy$1,001 - $15,000
- David Taylorhouse · OH02 · disclosed May 8, 2026 (11d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 9, 2026 (10d later)Buy$15,001 - $50,000
- Gilbert Cisneroshouse · CA31 · disclosed Mar 10, 2026 (28d later)Sell$1,001 - $15,000
- David Taylorhouse · OH02 · disclosed Feb 23, 2026 (13d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Feb 13, 2026 (35d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (28d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$1,001 - $15,000
- David Taylorhouse · OH02 · disclosed Feb 3, 2026 (18d later)Buy$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Jan 16, 2026 (29d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Dec 12, 2025 (29d later)Sell$1,001 - $15,000
- David Taylorhouse · OH02 · disclosed Nov 19, 2025 (16d later)Buy$1,001 - $15,000
- Byron Donaldshouse · FL19 · disclosed Nov 19, 2025 (41d later)Buy$1,001 - $15,000
- Byron Donaldshouse · FL19 · disclosed Nov 19, 2025 (26d later)Buy$1,001 - $15,000
- Byron Donaldshouse · FL19 · disclosed Nov 19, 2025 (41d later)Buy$1,001 - $15,000
- Sheldon Whitehousesenate · RI · disclosed Nov 3, 2025 (7d later)Sell$15,001 - $50,000
- Val Hoylehouse · OR04 · disclosed Oct 10, 2025 (17d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
